Orchard Therapeutics has pledged to work to convince NICE about the value of its gene therapy, Libmeldy (atidarsagene autotemcel), after the health technology assessment (HTA) body recommended against making the treatment available on England’s National Health Service for children with metachromatic leukodystrophy (MLD).
In draft guidance, released for public consultation on 9 June, NICE said it recognized that Libmeldy was an “innovative technology...







